Skip to main content
Premium Trial:

Request an Annual Quote

Jeffrey Vick

Premium
Silence Therapeutics has named Jeffrey Vick as its new CEO.
 
The company said it appointed Vick to “strengthen its core management team as [it] seeks to expand its business partnerships.” Silence has not had a CEO since it began refocusing on RNAi therapeutics in 2004 (see RNAi News, 7/29/2005).
 
Vick previously served in senior management at DepoTech, was vice president of corporate development for Cytoyia, vice president of business development at Genset, and vice president of corporate development and intellectual property at Centelion.
 
He holds a BS in chemistry from the University of Virginia, and an MS in chemistry from the University of California, San Diego. He also holds an MBA from Stanford Graduate School of Business.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.